Detalles del proyecto
| Estado | Finalizado |
|---|---|
| Fecha de inicio/Fecha fin | 8/30/23 → 8/30/26 |
Financiación
- ImmunoGen Inc: 24.157,00 US$
IMGN853-0421/GOG-3078: Randomized, Multicenter, Open-label, Phase 3 study of Mirvetuximab Soravtansine in Combination with Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients with FRa-positive Recurrent Platinum-sensitive Epithelial o
- Miller, Rachel (PI)